share_log

HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42

HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42

HC Wainwright & Co.将Landos Biopharma的评级下调至中性,将目标股价下调至20.42美元
Moomoo 24/7 ·  04/01 07:12

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and lowers the price target from $50 to $20.42.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱将兰多斯生物制药(纳斯达克股票代码:LABP)的评级从买入下调至中性,并将目标股价从50美元下调至20.42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发